Drugs / 18F-NOTA-ABY-030
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07217028 | Apr 2026 → Apr 2029 expected | head and neck squamous cell carcinoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-NOTA-ABY-030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07217028 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic performance of \[18F\]NOTA-ABY-030” NCT07217028 ↗ |
| Target | EGFR | “radiolabeled anti-EGFR affibody” NCT07217028 ↗ |